Abstract
Angiotensin II receptor blockers as a class are reported to act as insulin sensitizers. Of these, telmisartan has been shown to have additional unique peroxisome proliferator-activated receptor-gamma-mediated, insulin-sensitizing properties. In this study, investigators explored the effects of telmisartan on glycemic control and lipid metabolism in hypertensive patients with type 2 diabetes who had switched to telmisartan from another angiotensin II receptor blocker. The study subjects were 42 hypertensive outpatients with type 2 diabetes who were being treated with candesartan 8 mg/d and who agreed to switch to treatment with telmisartan 40 mg/d. Relevant laboratory variables were measured 6 mo before treatment switching, at the time of switching, and 6 mo after switching. No significant differences were noted in blood pressure, body mass index, or glycosylated hemoglobin among subjects before and after therapy was switched. No adverse reactions such as edema or hepatic toxicity were noted. No significant changes in fasting plasma glucose, fasting insulin, HOMA-R (insulin resistance as measured by the homeostasis model), preheparin lipoprotein lipase mass, high-density lipoprotein cholesterol, and free fatty acids were noted. Triglyceride levels were significantly decreased, however, and adiponectin levels were significantly increased (8.1±3.1 μg/mL at switching; 8.6±3.0 μg/mL 6 mo after switching;P<.01) after the switch to telmisartan therapy. Study results show that telmisartan did not affect glycemic control, but it improved lipid metabolism and adiponectin production in patients with type 2 diabetes, suggesting that AT1-receptor antagonism and selective peroxisome proliferator-activated receptor-gamma activation by telmisartan combine to account for observed effects on lipid metabolism and adiponectin production.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Lindholm L, Ibsen H, Bolch-Johnsen K, et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.J Hypertens. 2002;20:1879–1886.
Yusuf S, Ostergren JB, Gerstein HC, et al. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure.Circulation. 2005;112:48–53.
Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial.Lancet. 2004;63:2022–2031.
Shiuchi T, Iwai M, Li HS, et al. Angiotensin II type 1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice.Hypertension. 2004;43:1003–1010.
Velloso LA, Folli F, Sun XJ, White MF, Saad MJ, Kahn CR. Cross-talk between the insulin and angiotensin signaling systems.Proc Natl Acad Sci USA. 1996;93:12490–12495.
Schling P, Loffler G. Effects of angiotensin II on adipose conversion and expression of genes of the renin-angiotensin system in human preadipocytes.Horm Metab Res. 2001;33:189–195.
Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM. Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors.Diabetes. 2002;51:1699–1707.
Furuhashi M, Ura N, Takizawa H, et al. Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity.J Hypertens. 2004;22:1977–1982.
Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity.Hypertension. 2004;43:993–1002.
Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activating receptor-γ activity.Circulation. 2004;109:2054–2057.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment-insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man.Diabetologia. 1985;28:412–419.
Kobayashi J, Hashimoto H, Fukamachi I, et al. Lipoprotein lipase mass and activity in severe hypertriglyceridemia.Clin Chim Acta. 1993;216:113–123.
Pershadsingh HA, Kurtz TW. Insulin-sensitizing effects of telmisartan.Diabetes Care. 2004; 27:1015.
Miura Y, Yamamoto N, Tsunekawa S, et al. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes.Diabetes Care. 2005;28:757–758.
Vitale C, Mercuro G, Castiglioni C, et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome.Cardiovasc Diabetol. 2005;4:6.
Okada K, Hirano T, Ran J, Adachi M. Olmesartan medoxomil, an angiotensin II receptor blocker, ameliorates insulin resistance and decreases triglyceride production in fructose-fed rats.Hypertens Res. 2004;27:293–299.
Rangwala SM, Lazar MA. PPARγ in diabetes and metabolism.Trends Pharmacol Sci. 2004;25: 331–336.
Iwaki M, Matsuda M, Maeda N, et al. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors.Diabetes. 2003;52:1655–1663.
Maeda N, Takahashi M, Funahashi T, et al. PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein.Diabetes. 2001;50:2094–2099.
Clasen R, Schupp M, Foryst-Ludwig A, et al. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin.Hypertension. 2005;46:137–143.
Mori Y, Murakawa Y, Okada K, et al. Effect of troglitazone on body fat distribution in type 2 diabetic patients.Diabetes Care. 1999;22:908–912.
Schupp M, Clemenz M, Gineste R, et al. Molecular characterization of new selective peroxisome proliferator-activated receptor γ modulators with angiotensin receptor blocking activity.Diabetes. 2005;54:3442–3452.
Sugimoto K, Qi NR, Kazdova L, Pravenec M, Ogihara T, Kurtz TW. Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis.Hypertension. 2006;47:1–7.
Araki K, Masaki T, Katsuragi I, Tanaka K, Kakuma T, Yoshimatsu H. Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in diet-induced obese mice.Hypertension. 2006;48:1–7.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mori, Y., Itoh, Y. & Tajima, N. Telmisartan improves lipid metabolism and adiponectin production but does not affect glycemic control in hypertensive patients with type 2 diabetes. Adv Therapy 24, 146–153 (2007). https://doi.org/10.1007/BF02850002
Issue Date:
DOI: https://doi.org/10.1007/BF02850002